REFERENCES
- National Board of Health and Welfare. The Cancer Registry. Cancer incidence in Sweden in 1992. Stock-holm: National Board of Health and Welfare, 1995: 15.
- National Central Bureau of Statistics Causes of death 1993. Stockholm: National Central Bureau of Statistics, 1995: 24.
- Cooner WH. Prostate-specific antigen, digital rectal examination, and transrectal ultrasonic examination of the prostate in prostate cancer detection. Monogr Urol 1991; 12: 3–13.
- Gustafsson O, Norming U, Almgard L-E, Fredriksson A, Gustavsson G, Harvig B, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. J Urol 1992; 148: 1827–31.
- Aus G, Bergdahl S, Hugosson J, Lodding P. Norlen L. Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate-specific antigen. Scand J Urol Nephrol 1994; 28: 379–84.
- Benson MC, McMahon DJ, Cooner WH, Olsson CA. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen density. World J Urol 1993; 11: 206–13.
- Semjonow A, Hamm M, Rathert P. Hertle L. Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol 1994; 73: 538–43.
- Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha FS, Redwine EA, et al. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076–83.
- Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.
- Myrtle if, Klimley PG, Ivor LP, Bruni If. Clinical utility of prostate specific antigen (PSA) in the manage-ment of prostatic cancer. Advances in cancer diagnosis. San Diego: Hybritech Inc., 1986: 2–3.
- Collins GN, Lee RJ, McKelvie GB, Rogers ACN, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 1993; 71: 445.
- Oesterling JE, Jacobsen SJ, Christopher GC, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. JAMA 1993; 270: 860–4.
- Gustafsson O, Carlsson P. Norming U, Nyman CR, Svensson H. Cost-effectiveness analysis in early detec-tion of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men. Prostate 1995; 26: 299–309.
- Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumors. In: Mostofi FK. International Histological Classification of Tumors No. 22. Geneva: World Health Organization, 1980: 1–26.
- Esposti PL. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. A five-year follow-up study of 469 hormonal-treated patients. Scand J Urol Nephrol 1971; 5: 199.
- Draper NR, Smith H. Applied regression analysis, New York: Wiley, 1966: 24.
- Begg CB. Methodological issues in studies of the treat-ment, diagnosis, and etiology of prostate cancer. Semin Oncol 1994; 21: 569–79.
- Bangma C, Kranse R, Blijenberg B, Schröder F. The value of screening tests in the detection of prostate cancer. Part I. Results of a retrospective evaluation of 1,726 men. Urology 1995: 46, 773–8.
- Hoedemaeker RF, Rietbergen JBW, Kranse R, van der Kwast TH, Schröder FH. Comparison of pathologic characteristics of Tic and non-Tic cancers detected in a population-based screening study, the European Ran-domized Study of Screening for Prostate Cancer. World J Urol 1997; 15: 339–45.